IFITM Proteins That Restrict the Early Stages of Respiratory Virus Infection Do Not Influence Late-Stage Replication

• Published in: Journal of virology Vol. 95; no. 20; p. e0083721
• Main Authors: Meischel, Tina, Fritzlar, Svenja, Villalon-Letelier, Fernando, Tessema, Melkamu B, Brooks, Andrew G, Reading, Patrick C, Londrigan, Sarah L
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 27.09.2021
• Subjects: A549 Cells; Antigens, Differentiation - metabolism; Cell Line, Tumor; Cell Membrane - metabolism; Endocytosis - physiology; Host-Pathogen Interactions - physiology; Humans; Influenza A virus - metabolism; Influenza A virus - pathogenicity; Interferons - metabolism; Membrane Proteins - metabolism; Parainfluenza Virus 3, Human - metabolism; Parainfluenza Virus 3, Human - pathogenicity; RNA-Binding Proteins - metabolism; Virology; Virus Diseases - metabolism; Virus Internalization; Virus Replication - physiology; Virus-Cell Interactions; IFITM; influenza; host restriction factors; parainfluenza virus
• DOI: 10.1128/JVI.00837-21
• ISSN: 0022-538X

Interferon-induced transmembrane (IFITM) proteins inhibit a broad range of enveloped viruses by blocking entry into host cells. We used an inducible overexpression system to investigate if IFITM1, IFITM2, and IFITM3 could modulate early and/or late stages of influenza A virus (IAV) or parainfluenza virus 3 (PIV-3) infection in human A549 airway epithelial cells. IAV and PIV-3 represent respiratory viruses which utilize distinct cellular entry pathways. We verify entry by endocytosis for IAV, whereas PIV-3 infection was consistent with fusion at the plasma membrane. Following induction prior to infection, all three IFITM proteins restricted the percentage of IAV-infected cells at 8 hours postinfection. In contrast, prior induction of IFITM1 and IFITM2 did not inhibit PIV-3 infection, although a modest reduction was observed with IFITM3. Small interfering RNA (siRNA)-mediated knockdown of endogenous IFITM1, IFITM2, and IFITM3 expression, in the presence or absence of pretreatment with type I interferon, resulted in increased IAV, but not PIV-3, infection. This finding suggests that while all three IFITMs display antiviral activity against IAV, they do not restrict the early stages of PIV-3 infection. IAV and PIV-3 infection culminates in viral egress through budding at the plasma membrane. Inducible expression of IFITM1, IFITM2, or IFITM3 immediately after infection did not impact titers of infectious virus released from IAV- or PIV-3-infected cells. Our findings show that IFITM proteins differentially restrict the early stages of infection of two respiratory viruses with distinct cellular entry pathways but do not influence the late stages of replication for either virus. Interferon-induced transmembrane (IFITM) proteins restrict the initial stages of infection for several respiratory viruses; however, their potential to modulate the later stages of virus replication has not been explored. In this study, we highlight the utility of an inducible overexpression system to assess the impact of IFITM proteins on either early- or late-stage replication of two respiratory viruses. We demonstrate antiviral activity by IFITM1, IFITM2, and IFITM3 against influenza A virus (IAV) but not parainfluenza virus 3 (PIV-3) during the early stages of cellular infection. Furthermore, IFITM induction following IAV or PIV-3 infection does not restrict the late stages of replication of either virus. Our findings show that IFITM proteins can differentially restrict the early stages of infection of two viruses with distinct cellular entry pathways and yet do not influence the late stages of replication for either virus.